UCB SA UCBJY Stock
UCB SA Price Chart
UCB SA UCBJY Financial and Trading Overview
| UCB SA stock price | 130.36 USD |
| Previous Close | 129.33 USD |
| Open | 131.13 USD |
| Bid | 129.13 USD x 37500 |
| Ask | 129.32 USD x 20000 |
| Day's Range | 128.72 - 131.32 USD |
| 52 Week Range | 108.04 - 168.76 USD |
| Volume | 4.97K USD |
| Avg. Volume | 35.91K USD |
| Market Cap | 49.26B USD |
| Beta (5Y Monthly) | 0.182 |
| PE Ratio (TTM) | 19.750765 |
| EPS (TTM) | 6.54 USD |
| Forward Dividend & Yield | 0.85 (0.66%) |
| Ex-Dividend Date | May 5, 2026 |
| 1y Target Est | 164.27 USD |
UCBJY Valuation Measures
| Enterprise Value | 52.08B USD |
| Trailing P/E | 19.750765 |
| Forward P/E | 16.37676 |
| PEG Ratio (5 yr expected) | 1.42 |
| Price/Sales (ttm) | 5.7784805 |
| Price/Book (mrq) | 3.9603505 |
| Enterprise Value/Revenue | 6.11 |
| Enterprise Value/EBITDA | 15.583 |
Trading Information
UCB SA Stock Price History
| Beta (5Y Monthly) | 0.182 |
| 52-Week Change | 19.23% |
| S&P500 52-Week Change | 21.71% |
| 52 Week High | 168.76 USD |
| 52 Week Low | 108.04 USD |
| 50-Day Moving Average | 142.06 USD |
| 200-Day Moving Average | 143.95 USD |
UCBJY Share Statistics
| Avg. Volume (3 month) | 35.91K USD |
| Avg. Daily Volume (10-Days) | 63.95K USD |
| Shares Outstanding | 381.33M |
| Float | 239.23M |
| Short Ratio | N/A |
| % Held by Insiders | 0% |
| % Held by Institutions | 0.012% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 1.45 |
| Trailing Annual Dividend Yield | 1.12% |
| 5 Year Average Dividend Yield | 121.00% |
| Payout Ratio | 0.1286 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 25.73% |
| Operating Margin (ttm) | 33.32% |
| Gross Margin | 76.21% |
| EBITDA Margin | 39.20% |
Management Effectiveness
| Return on Assets (ttm) | 8.97% |
| Return on Equity (ttm) | 20.56% |
Income Statement
| Revenue (ttm) | 8.52B USD |
| Revenue Per Share (ttm) | 22.38 USD |
| Quarterly Revenue Growth (yoy) | 22.50% |
| Gross Profit (ttm) | 6.5B USD |
| EBITDA | 3.34B USD |
| Net Income Avi to Common (ttm) | 2.19B USD |
| Diluted EPS (ttm) | 6.54 |
| Quarterly Earnings Growth (yoy) | 133.90% |
Balance Sheet
| Total Cash (mrq) | 766M USD |
| Total Cash Per Share (mrq) | 2.01 USD |
| Total Debt (mrq) | 3.59B USD |
| Total Debt/Equity (mrq) | 30.79 USD |
| Current Ratio (mrq) | 1.203 |
| Book Value Per Share (mrq) | 32.6158 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 1.95B USD |
| Levered Free Cash Flow (ttm) | 1.1B USD |
Profile of UCB SA
| Country | United States |
| State | N/A |
| City | Brussels |
| Address | Allée de la Recherche, 60 |
| ZIP | 1070 |
| Phone | 32 2 559 99 99 |
| Website | https://www.ucb.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 9000 |
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson's disease and restless legs syndrome. It also provides Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. In addition, the company offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx to treat plaque psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; Fintepla for the treatment of Dravet and Lennox-Gastaut syndrome; and RYSTIGGO and ZILBRYSQ to treat people living with generalized myasthenia gravis. Further, it develops KYGEVVI (doxecitine/doxribtimine) for thymidine kinase 2 deficiency disorder; fenfluramine to treat CDKL5 deficiency disorder, and RETT-Syndrome; dapirolizumab pegol for systemic lupus erythematosus; STACCATO alprazolam for treating stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; and UCB9741 for atopic dermatitis, non cystic fibrosis bronchiectasis, and chronic obstructive pulmonary disease. Additionally, it engages in the contract manufacturing activities. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
Q&A For UCB SA Stock
What is a current UCBJY stock price?
UCB SA UCBJY stock price today per share is 130.36 USD.
How to purchase UCB SA stock?
You can buy UCBJY shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for UCB SA?
The stock symbol or ticker of UCB SA is UCBJY.
Which industry does the UCB SA company belong to?
The UCB SA industry is Biotechnology.
How many shares does UCB SA have in circulation?
The max supply of UCB SA shares is 381.33M.
What is UCB SA Price to Earnings Ratio (PE Ratio)?
UCB SA PE Ratio is 19.93272200 now.
What was UCB SA earnings per share over the trailing 12 months (TTM)?
UCB SA EPS is 6.54 USD over the trailing 12 months.
Which sector does the UCB SA company belong to?
The UCB SA sector is Healthcare.
